Study Details
Testing the Drug Depemokimab for Adults with Hypereosinophilic Syndrome
(IRB#: IRB_00158126)
Hypereosinophilic syndrome (HES) is caused by a high amount of white blood cells, damaging body organs. This study will test a drug called Depemokimab to treat people with HES. The study wants to see if the drug will help people with the syndrome and is safe. People in this study will be treated with Depemokimab or a placebo. The placebo looks like the study drug but does not have the medication. Being in this study requires attending in-person visits to the study clinic about 18 times over 14 months. Medical tests will be done during the study to track the health of participants.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 18 years and older
- Diagnosed with Hypereosinophilic Syndrome
- Have had 2 Hypereosinophilic Syndrome flares in the past 12 months
- Able to attend in-person visits at the medical clinic
Exclusion Criteria
- Ongoing active infection requiring treatment
- History or current specific cancer or cancer in remission for less than 5 years before participation
- Liver disease
- History of alcohol misuse or substance abuse within 2 years before participation
- Pregnant or breastfeeding
Will I be paid for my time?
Yes
IRB#: IRB_00158126
PI: Mili Shum
Department: DERMATOLOGY
Approval Date: 2023-03-16 06:00:00
Specialties: Dermatology
I am Interested